These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 29435980)

  • 1. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.
    Batista AF; Forny-Germano L; Clarke JR; Lyra E Silva NM; Brito-Moreira J; Boehnke SE; Winterborn A; Coe BC; Lablans A; Vital JF; Marques SA; Martinez AM; Gralle M; Holscher C; Klein WL; Houzel JC; Ferreira ST; Munoz DP; De Felice FG
    J Pathol; 2018 May; 245(1):85-100. PubMed ID: 29435980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model.
    Qi L; Ke L; Liu X; Liao L; Ke S; Liu X; Wang Y; Lin X; Zhou Y; Wu L; Chen Z; Liu L
    Eur J Pharmacol; 2016 Jul; 783():23-32. PubMed ID: 27131827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Niehoff ML; Morley JE; Jelsing J; Pyke C; Knudsen LB; Farr SA; Vrang N
    J Alzheimers Dis; 2015; 46(4):877-88. PubMed ID: 25869785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis.
    Yan W; Pang M; Yu Y; Gou X; Si P; Zhawatibai A; Zhang Y; Zhang M; Guo T; Yi X; Chen L
    Life Sci; 2019 Aug; 231():116566. PubMed ID: 31201846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide Protects Against Brain Amyloid-β
    Duarte AI; Candeias E; Alves IN; Mena D; Silva DF; Machado NJ; Campos EJ; Santos MS; Oliveira CR; Moreira PI
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32143329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.
    Long-Smith CM; Manning S; McClean PL; Coakley MF; O'Halloran DJ; Holscher C; O'Neill C
    Neuromolecular Med; 2013 Mar; 15(1):102-14. PubMed ID: 23011726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
    Holubová M; Hrubá L; Popelová A; Bencze M; Pražienková V; Gengler S; Kratochvílová H; Haluzík M; Železná B; Kuneš J; Hölscher C; Maletínská L
    Neuropharmacology; 2019 Jan; 144():377-387. PubMed ID: 30428311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astrocyte Transforming Growth Factor Beta 1 Protects Synapses against Aβ Oligomers in Alzheimer's Disease Model.
    Diniz LP; Tortelli V; Matias I; Morgado J; Bérgamo Araujo AP; Melo HM; Seixas da Silva GS; Alves-Leon SV; de Souza JM; Ferreira ST; De Felice FG; Gomes FCA
    J Neurosci; 2017 Jul; 37(28):6797-6809. PubMed ID: 28607171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
    Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes.
    Infante-Garcia C; Ramos-Rodriguez JJ; Hierro-Bujalance C; Ortegon E; Pickett E; Jackson R; Hernandez-Pacho F; Spires-Jones T; Garcia-Alloza M
    Mol Neurobiol; 2018 Jul; 55(7):6130-6144. PubMed ID: 29224179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-Mediated Transduction of Insulin-Like Growth Factor 1 Protects Hippocampal Neurons from the Toxicity of Aβ Oligomers and Prevents Memory Loss in an Alzheimer Mouse Model.
    Selles MC; Fortuna JTS; Zappa-Villar MF; de Faria YPR; Souza AS; Suemoto CK; Leite REP; Rodriguez RD; Grinberg LT; Reggiani PC; Ferreira ST
    Mol Neurobiol; 2020 Mar; 57(3):1473-1483. PubMed ID: 31760608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capsaicin Attenuates Amyloid-β-Induced Synapse Loss and Cognitive Impairments in Mice.
    Chen L; Huang Z; Du Y; Fu M; Han H; Wang Y; Dong Z
    J Alzheimers Dis; 2017; 59(2):683-694. PubMed ID: 28671132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity.
    Jantrapirom S; Nimlamool W; Chattipakorn N; Chattipakorn S; Temviriyanukul P; Inthachat W; Govitrapong P; Potikanond S
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of amyloid-β (Aβ) oligomers with neurexin 2α and neuroligin 1 mediates synapse damage and memory loss in mice.
    Brito-Moreira J; Lourenco MV; Oliveira MM; Ribeiro FC; Ledo JH; Diniz LP; Vital JFS; Magdesian MH; Melo HM; Barros-Aragão F; de Souza JM; Alves-Leon SV; Gomes FCA; Clarke JR; Figueiredo CP; De Felice FG; Ferreira ST
    J Biol Chem; 2017 May; 292(18):7327-7337. PubMed ID: 28283575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic sleep restriction promotes brain inflammation and synapse loss, and potentiates memory impairment induced by amyloid-β oligomers in mice.
    Kincheski GC; Valentim IS; Clarke JR; Cozachenco D; Castelo-Branco MTL; Ramos-Lobo AM; Rumjanek VMBD; Donato J; De Felice FG; Ferreira ST
    Brain Behav Immun; 2017 Aug; 64():140-151. PubMed ID: 28412140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting.
    Zhang Y; Xie JZ; Xu XY; Hu J; Xu T; Jin S; Yang SJ; Wang JZ
    Neurosci Bull; 2019 Aug; 35(4):724-734. PubMed ID: 30632006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by β-amyloid oligomers in an acute mouse model of Alzheimer's disease.
    Balducci C; Frasca A; Zotti M; La Vitola P; Mhillaj E; Grigoli E; Iacobellis M; Grandi F; Messa M; Colombo L; Molteni M; Trabace L; Rossetti C; Salmona M; Forloni G
    Brain Behav Immun; 2017 Feb; 60():188-197. PubMed ID: 27751869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.